top of page

Scientific Publications since 2013 (Google Scholar H Factor 78; Pubmed bibliography)

250. Patel D, Senecal J, Spellberg B, Morris AM, Saxinger L, Footer BW, McDonald EG, Lee TC.  Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada.  2023.  JAC Antimicrob Resist.  5(1):dlac138.

249. Nielsen TB, Yan J, Slarve M, Li R, Junge JA, Luna BM, Wilkinson I, Yerramalla U, Spellberg B.  Development of a bispecific antibody targeting clinical isolates of Acinetobacter baumannii.  2023.  J Infect Dis.  ePub.

248. Davar K, Clark D, Centor RM, Dominguez F, Ghanem B, Lee R, Lee TC, McDonald EG, Phillips MC, Sendi P, Spellberg B.  Can the Future of ID Escape the Inertial Dogma of Its Past?: The Exemplars of Shorter Is Better and Oral Is the New IV.  2022. ePub.

247. Terp S, Reichert Z, Burner E, Randhawa J, Axeen S, Messina M, Dworkis DA, Menchine M, Lam CN, Banerjee J, Spellberg B, Arora S.  Characteristics and Outcomes of 360 Consecutive COVID-19 Patients Discharged From the Emergency Department With Supplemental Oxygen.  Ann Emerg Med. 2023. 81:14-19.

246. Imlay H, Spellberg B.  Shorter is better: The case for short antibiotic courses for common infections in solid organ transplant recipients.  Transpl Infect Dis.  2022.  24(5):e13896.

245. Miller S, Goy K, She R, Spellberg B, Luna B.  Antimicrobial Susceptibility Testing Performed in RPMI 1640 Reveals Azithromycin Efficacy against Carbapenem-Resistant Acinetobacter baumannii and Predicts In Vivo Outcomes in Galleria mellonella.  2022.  ePub.

244. Lee RA, Stripling JT, Spellberg B, Centor RM.  Short course antibiotics for common infections: what do we Know and where do we go from here?  2022.  ePub.

243. Dominguez F, Gaffin N, Davar K, Wald-Dickler N, Minejima E, Werge D, Holtom P, Spellberg B, Baden R.  How to change the course: Practical aspects of implementing Shorter is Better.  Clin Microbiol Infection.  2022.  ePub.

242. Dang J, Goel P, Choi KJ, Massenzio E, Landau MJ, Pham CH, Huang S, Yenikomshian HA, Spellberg B, Gillenwater TJ.  Mucormycosis following burn injuries: A systematic review.  Burns.  2022.  ePub.

241. Maeusli M, Skandalis N, Lee B, Lu P, Miller S, Yan J, Talyansky Y, Li R, Reyna Z, Guerrero N, Ulhaq A, Slarve M, Theologidis I, Spellberg B, Luna B.  Acacia Fiber Protects the Gut from Extended-Spectrum Beta-Lactamase (ESBL)-Producing Escherichia coli Colonization Enabled by Antibiotics.  mSphere.  2022.  7(3):e0007122.

240. Spellberg B, Aggrey G, Brennan MB, Footer B, Forrest G, Hamilton F, Minejima E, Moore J, Ahn J, Angarone M, Centor RM, Cherabuddi K, Curran J, Davar K, Davis J, Qin Dong M, Ghanem B, Hutcheon D, Jent P, Kang M, Lee R, McDonald E, Morris AM, Reece R, Schwartz IS, So M, Tong S, Tucker C, Wald-Dickler N, Weinstein EJ, Williams II R, Yen C, Zhou 0S, Lee TC, on behalf of WikiGuidelines.  Management of Pyogenic Osteomyelitis in Adults: A WikiGuidelines Consensus Statement.  JAMA Network Open.  2022.  5(5):e2211321.

239. Spellberg B, Rice LB.  The Shorter Is Better movement: past, present, future.  Clin Microbiol Infect.  2022.  ePub.

238. Chambers TN, Opas L, Spellberg B.  A Collaborative Approach to Safety, Equity, and Fairness by Medical Staff, Graduate Medical Education, Human Resources, and Law Enforcement.  J Grad Med Educ.  2021.  13:768-70.

237. Wald-Dickler N, Lee TC, Tangpraphaphorn S, Butler-Wu SM, Wang N, Degener T, Kan C, Phillips MC, Cho E, Canamar C, Holtom P, Spellberg B.  Fosfomycin versus Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter, Retrospective Cohort

Study.  Open Forum Infect Dis.  9(1):ofab620. doi: 10.1093/ofid/ofab620. 

236. Gaffin N, Spellberg B.  Sustained reductions in unnecessary antimicrobial administration and hospital Clostridioides difficile rates via stewardship in a nonacademic setting.  2021.  Infect Control Hospital Epidemiol.  ePub.

235. Centor RM, Spellberg B, Shaneyfelt T.  Annals on Call—Guidelines with Humility.  2021.  Ann Int Medicine.  174(12):OC1. doi: 10.7326/A20-0026.

234. Lee B, Yan J, Ulhaq A, Miller S, Seo W, Lu P, She R, Spellberg B, Luna B.  In Vitro and In Vivo Activity of Rifabutin and Rifampin against Antibiotic-Resistant A. baumannii, E. coli, S. aureus, P. aeruginosa, and K. pneumoniae.  2021.  mSphere.  6(6):e0092021.

233. Wald-Dickler N, Holtom PD, Phillips MC, Centor RM, Lee RA, Baden R, Spellberg B.  Oral Is the New IV--Challenging Decades of Blood and Bone Infection Dogma: A Systematic Review. 2021.  Am J Med.  S0002-9343(21)00699-9.

232. Spellberg B, Shorr AF.  Opinion-Based Recommendations: Beware the Tyranny of Experts.  2021.  Open Forum Infect Dis.  8(11):ofab490.

231. Spellberg B, Wright WF, Shaneyfelt T, Centor RM.  The Future of Medical Guidelines—Standardizing Clinical Care with the Humility of Uncertainty.  Ann Int Med.  2021.  174(12):1740-1742.

230. Masood M, Panek D, Butler-Wu S, Spellberg B.  A pain in the flank.  Infect Dis Clinical Practice.  2021.  30:e1120.

229. Phillips MC, Sarff L, Banerjee J, Coffey C, Holtom P, Meurer S, Wald-Dickler N, Spellberg B.  Effect of Mortality from COVID-19 on Inpatient Outcomes.  J Medical Virol.  2021.  94(1):318-326.

228. Hinchliffe P, Moreno DM, Rossi MA, Mojica MF, Martinez V, Villamil V, Spellberg B, Drusano GL, Banchio C, Mahler G, Bonomo RA, Vila AJ, Spencer J.  2-Mercaptomethyl Thiazolidines (MMTZs) Inhibit All Metallo-β-Lactamase Classes by Maintaining a Conserved Binding Mode.  ACS Infect Dis.  2021.  7:2697-2706.

227. Nielsen TB, Yan J, Slarve M, Lu P, Li R, Ruiz J, Lee B, Burk E, Talyansky Y, Oelschlaeger P, Hurth K, Win W, Luna BM, Bonomo RA, Spellberg B.  Monoclonal Antibody Therapy against Acinetobacter baumannii.  Infection Immun.  2021.  89(10):e0016221.

226. Rossi MA, Martinez V, Hinchliffe P, Mojica MF, Castillo V, Moreno DM, Smith R, Spellberg B, Drusano GL, Banchio C, Bonomo RA, Spencer J, Vila AJ, Mahler G.  2-Mercaptomethyl-thiazolidines use conserved aromatic-S interactions to achieve broad-range inhibition of metallo-β-lactamases.  Chem Sci.  2021.  12:2898-2908.

225. Feldman BJ, Kim JS, Mosqueda L, Vongsachang H, Banerjee J, Coffey CE Jr, Spellberg B, Hochman M, Robinson J.  From the hospital to the streets: Bringing care to the unsheltered homeless in Los Angeles.  2021.  Healthc (Amst).  9:00557.

224. Nielsen TB, Yan J, Luna BM, Talyansky Y, Slarve M, Bonomo RA, Spellberg B.  Monoclonal antibody requires immunomodulation for efficacy against Acinetobacter baumannii infection.  J Infect Dis.  2021.  224(12):2133-2147.

223. Centor RM, Lee RA, Spellberg B.  Web Exclusive. Annals On Call - The Right Antibiotic, for the Right Infection, and for the Right Duration.  Ann Int Med.  2021.  174(5):OC1.

222. Sargent RE, Sener SF, Amaya R, Vazquez E, Bowdish ME, Spellberg B.  SARS-CoV-2-related outcomes after surgical procedures on SARS-CoV-2-positive patients in a large, urban, safety net medical center.  Surg Open Sci.  2021.  5:10-13.

221. Banerjee J, Canamar CP, Voyageur C, Tangpraphaphorn S, Lemus A, Coffey Jr C, Wald-Dickler N, Holtom P, Shoenberger J, Bowdish M, Yee HF, Spellberg B.  Mortality and Readmission Rates Among Patients With COVID-19 After Discharge From Acute Care Setting With Supplemental Oxygen.  JAMA Open Network.  2021. 4(4):e213990.

220. Jorgensen S, Spellberg B, Shorr AF, Wright WF.  Should Therapeutic Drug Monitoring Based on the Vancomycin Area Under the Concentration-Time Curve Be Standard for Serious Methicillin-Resistant Staphylococcus aureus Infections? - No.  Clin Infect Dis. 72:1502-1506.

219. Minejima E, Wang J, Boettcher S, Liu L, Lou M, She RC, Wenzel SL, Spellberg B, Wong-Beringer A.  Distance Between Home and the Admitting Hospital and Its Effect on Survival of Low Socioeconomic Status Population With Staphylococcus aureus Bacteremia.  Public Health Rep.  2021.  137(1):110-119.

218. ACTIV-3/TICO LY-CoV555 Study Group, Lundgren JD, Grund B, Barkauskas CE, et al.  A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.  New Eng J Med.  2021.  384(10):905-914.

217. Talyansky Y, Nielsen TB, Yan J, Carlino-Macdonald U, Di Venanzio G, Chakravorty S, Ulhaq A, Feldman MF, Russo TA, Vinogradov E, Luna B, Wright MS, Adams MD, Spellberg B.  Capsule carbohydrate structure determines virulence in Acinetobacter baumannii.  PLoS Pathogens.  2021.  7:e1009291.  PMCID: PMC7880449.

216. Cheng J, Yan J, Reyna Z, Slarve M, Lu P, Spellberg B, Luna B.  Synergistic rifabutin and colistin reduce emergence of resistance when treating Acinetobacter baumannii.  Antimicrob Agents Chemother.  2021.  65:e02204-20.

215. Spellberg B, Nielsen TB, Casadevall A.  Antibodies, Immunity, and COVID-19.  JAMA Internal Medicine.  181(4):460-462.

214. Luu A, Dominguez F, Yeshoua B, Vo C, Nallapa S, Chung D, Wald-Dickler N, Butler-Wu SM, Khaleel H, Chang K, Canamar C, Holtom P, Spellberg B.  Reducing Catheter Associated Urinary Tract Infections via Cost-Saving Diagnostic Stewardship.  Clin Infect Dis.  72(11):e883-e886.

213. Phillips MC, Wald-Dickler N, Loomis K, Luna BM, Spellberg B.  2020.  Pharmacology, Dosing, and Side Effects of Rifabutin as a Possible Therapy for Antibiotic-Resistant Acinetobacter Infections.  Open Forum Infect Dis.  7(11):ofaa460.

212. Wright WF, Jorgenson SCJ, Spellberg B.  Heaping the Pelion of Vancomycin on the Ossa of MRSA: Back to Basics in Clinical Care and Guidelines.  2020.  Clin Infect Dis. 72(10):e682-e684.

211. Spellberg B.  Alignment with Market Forces: The “Re-Whithering” of Infectious Diseases.  2020.  Open Forum Infect Dis.  20;7(8):ofaa245.  PMCID: PMC7397831.

210. Luna B, Trebosc V, Lee B, Bakowski M, Ulhaq A, Yan J, Lu P, Cheng J, Nielsen T, Lim J, Ketphan W, Eoh H, McNamara C, Skandalis N, She R, Kemmer C, Lociuro S, Dale GE, Spellberg B.  A Novel Screen Unmasks Rifabutin Hyperactivity for XDR Acinetobacter baumannii.  Nature Microbiol.  5(9):1134-1143.  PMCID: PMC7483275.

209. Maeusli M, Lee B, Miller S, Reyna Z, Lu P, Yan J, Ulhaq A, Skandalis N, Spellberg B, Luna B. A. baylyi horizontal gene transfer to E. coli on lettuce and subsequent antibiotic resistance transmission to the gut microbiome.  2020.  mSphere.  5(3):e00329-20.  PMCID: PMCID: PMC7253597.

208. Spellberg B, Haddix M, Lee R, Butler-Wu S, Holtom P, Yee H, Gounder P.  Community Prevalence of SARS-CoV-2 Among Patients with Influenza-Like Illnesses Presenting to a Los Angeles Medical Center in March 2020.  2020.  JAMA.  323(19):1966-7.  PMCID: PMCID: PMC7110920.

208. Spellberg B, Chambers HF, Musher DM, Walsh TL, Bayer AS.  Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis: A Narrative Review.  2020  JAMA Int Med.  180(5):769-777.  PMCID: PMC7483894.

206. Shorr AF, Zilberberg M, Spellberg B, Kollef M.  Microbiologic Failure Despite Clinical Cure in Pneumonia: Cum Hoc and Post Hoc Ergo Propter Hoc.  2020.  Clin Infect Dis.  71(12):3042-3043.

205. Tolles J, Waterman G, Coffey CE Jr, Sandoval R, Fleischman RJ, Hess M, Sarff L, Lewis RJ, Spellberg B, on behalf of the BRAVE Study Group.  The Bed Rest Avoidance (BRAVE) Study.  PLoS One.  2020.  15(1):e0226332.

204. Spellberg B.  Are echinocandins superior in efficacy to azoles?  2020.  Clin Infect Dis.  70(9):2020-2021.

203. Wilson BM, Bessesen MT, Doros G, Brown ST, Saade E, Hermos J, Perez F, Skalweit M, Spellberg B, Bonomo RA.  Adjunctive Rifampin Therapy For Diabetic Foot Osteomyelitis in the Veterans Health Administration.  2019.  JAMA Network Open.  2(11):e1916003.  PMCID: PMCID: PMC6902814.

202. Spellberg B, Nielsen TB, Gilbert DN, Shorr AF, Brass EP.  Ensuring Sustainability of Needed Antibiotics: Aiming for the DART Board.  2019.  Ann Int Med.  171:580-2.  PMCID: PMC7296826.

201. Luna BM, Yan J, Reyna Z, Moon E, Nielsen TB, Reza H, Bonomo R, Louie A, Drusano G, Bulitta J, She R, Spellberg B.  Natural history of Acinetobacter baumannii infection in mice.  2019.  PLoS One.  14(7):e0219824. PMCID: PMC6638954.

200. Nielsen TB, Brass EP, Gilbert DN, Bartlett JG, Spellberg B.  Sustainable Antibiotic Discovery and Development--Is a Nonprofit Approach the Future?  2019.  New Eng J Med.  381:503-505. PMCID: PMC6697094.

199. Chau E, Sarkarati M, Spellberg B.  Adenosine Deaminase diagnostic testing in Pericardial Fluid.  2019.  JAMA.  322:163-4. PMCID: PMC6697089.

198. Spellberg B, Rice LB.  Duration of Antibiotic Therapy: Shorter is Better.  2019.  Ann Int Med.  171:210-11.  PMCID PMC6736742.

197. Adaptive Platform Trials Coalition (Collaborators listed alphabetically, Angus D…Spellberg B…Woodcock J).  Adaptive Platform Trials: Definition, Design, Conduct, and Reporting Considerations.  2019.  Nature Rev Drug Discovery.  18:797-807.

196. Cornely OA…Spellberg B…Chakrabarti A (>50 authors total).  Global Guideline for the Diagnosis and Management of Mucormycosis: An initiative of the ECMM in cooperation with ESCMID/EFISG.  2019.  Lancet Infect Dis.  19:e405-e421.

195. Luna BM, Nielsen TB, Cheng B, Pantapalangkoor P, Yan J, Boyle-Vavra S, Bruhn KW, Montgomery C, Spellberg B, Daum R.  Vaccines Targeting Staphylococcus aureus Skin and Bloodstream Infections Require Different Composition.  2019.  PloS One.  14(6):e0217439.  PMCID: PMC6557488.

194. Luna BM, Ershova K, Yan J, Ulhaq A, Nielsen TB, Hsieh S, Pantapalangkoor P, Van Scoy B, Ambrose P, Rudin S, Hujer K, Bonomo RA, Actis L, Skaar EP, Spellberg B.  Adjunctive transferrin to reduce the emergence of antibiotic resistance in Gram-negative bacteria.  2019.  J Antimicrob Chemother.  74:2631-9.  PMCID: PMC6736376.

193. Ambrose PG, VanScoy BD, Luna BM, Yan J, Ulhaq A, Nielsen TB, Rudin S, Hujer K, Bonomo RA, Actis L, Skaar E, Spellberg B.  Apotransferrin in Combination with Ciprofloxacin Slows Bacterial Replication, Prevents Resistance Amplification, and Increases Antimicrobial Regimen Effect.  2019.  Antimicrobial Agents Chemother.  63:e00112-19.  PMCID: PMC6496049.

192. Minejima E, Mai N, Bui N, Mert M, She RC, Nieberg P, Spellberg B, Wong-Behringer A.  Defining breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes.  2020.  Clin Infect Dis.  70(4):566-573.

191. Wald-Dickler N, Spellberg B.  Short Course Antibiotic Therapy—Replacing Constantine Units with “Shorter Is Better”.  2019.  Clin Infect Dis.  69:1476-1479.  PMCID PMC6792080

190. Choi YJ, Kim S, Nielsen TB, Yan J, Lu A, Ruan J, Remold-O’Donnell E, Lee H-R, Wu H, Spellberg B, Jung JU.  SerpinB1-mediated checkpoint of inflammatory caspase activation.  2019.  Nat Immunol.  20:276-287.  PMCID: PMC6450391.

189. Wong D, Holtom P, Spellberg B.  Osteomyelitis complicating sacral pressure ulcers: whether or not to treat with antibiotic therapy.  2019.  Clin Infect Dis.  68:338-42. PMCID: PMC6594415.

188. Yadav K, Masuda E, Minejima E, Spellberg B.  Expected Practice as a Novel Antibiotic Stewardship Intervention.  2018.  Open Forum Infect Disease.  6:ofy319.  PMCID: PMC6324551.

187. Gaffin N, Spellberg B.  Procalcitonin Trial Does Not Reflect Clinical Practice.  2018.  New Eng J Medicine.  379:1972-3.

186. Nielsen TB, Yan J, Luna B, Spellberg B.  Murine Oropharyngeal Aspiration Model of Ventilator-Associated and Hospital-Acquired Bacterial Pneumonia.  2018.  JoVE.  28 (136). PMCID: PMC6102004.

185. Tchesnokova VL, Rechkina E, Larson L, Ferrier K, Weaver JL, Schroeder DW, She R, Butler-Wu SM, Aguero-Rosenfeld ME, Zerr D, Fang FC, Ralston J, Riddell K, Scholes D, Weissman S, Parker K, Spellberg B, Johnson JR, Sokurenko EV.  Rapid and Extensive Expansion in the U.S. of a New Multidrug-Resistant Escherichia coli Clonal Group, Sequence Type ST1193.  Clin Infect Dis.  2018.  68:334-7.

184. Coffey C, Cho E, Wei E, Luu A, Ho M, Amaya R, Pecson M, Dalton F, Kahaku D, Spellberg B, Sener S.  Lean methods to improve operating room elective first case on-time starts in a large, urban, safety net medical center.  2018.  Am J Surg.  216:194-201.

183. Yen C, Holtom P, Butler-Wu S, Wald-Dickler N, Shulman I, Spellberg B.  Reducing Clostridium difficile colitis rates via cost-saving diagnostic stewardship.  2018.  Infection Control Hospital Epidem.  39:734-6.

182. Spellberg B.  The Maturing Antibiotic Mantra: “Shorter Is Still Better”.  2018.  J Hosp Med.  13:361-2.

181. Coffey C Jr, Carter V, Wei E, Hutcheon D, Gruen JP, Anonas-Ternate A, Sandoval R, Marquez A, Sarff L, Spellberg B.  No More “Code Black”: Intervention to Improve Inpatient Flow at a Large Public Hospital.  2018.  Am J Med.  131:371-376.

180. Wald-Dickler N, Holtom P, Spellberg B.  Busting the Myth of “Static vs. Cidal”: A Systematic Literature Review.  2017.  Clin Infect Dis.  66:1470-4.  PMCID: PMC5905615.

179. Barnes MD, Winkler ML, Taracila MA, Page MGP, Desarbre E, Kreiswirth BN, Shields RK, Nguyen MH, Clancy C, Spellberg B, Papp-Wallace KM, Bonomo RA.  Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic resistant phenotypes emerge from β-lactamase protein engineering.  2017.  mBio.  e00528-17.

178. Spellberg B.  Mucormycosis pathogenesis: Beyond Rhizopus.  2017.  Virulence.  8:1481-2.  PMCID: PMC5810489.

177. Nielsen TB, Pantapalangkoor P, Yan J, Luna BM, Dekitani K, Bruhn KW, Tan B, Junus J, Bonomo RA, Schmidt AM, Everson M, Duncanson F, Doherty TM, Lin L, Spellberg B.  Diabetes Exacerbates Infection via Hyperinflammation by Signaling through TLR4 and RAGE.  2017.  mBio.  8:e00818-17.  PMCID: PMC5565964.

176. Nielsen TB, Pantapalangkoor P, Luna BM, Bruhn KW, Yan J, Dekitani K, Hsieh S, Yeshoua B, Pascual B, Vinogradov E, Hujer KM, Domitrovic TN, Bonomo RA, Russo TA, Lesczcyniecka M, Schneider T, Spellberg B.  Monoclonal Antibody Protects against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis.  2017.  J Infect Dis.  216:489-501.  PMCID: PMC5853763.

175. Spellberg B.  Preserving the Health of the Public and Our Specialty.  2017.  Clin Infect Dis.  65:1597.

174. Luna BM, Ulhaq A, Yan J, Pantapalangkoor P, Nielsen T, Davies B, Actis L, Spellberg B.  Selectable markers for use in genetic manipulation of extreme drug resistant (XDR) Acinetobacter baumannii HUMC1.  2017.  mSphere.  2(2). pii: e00140-17.  PMCID: PMC5422034

173. Thompson GR III, Blair J, Wang S, Bercovitch R, Bolaris M, Van Den Akker D, Lopez R, Heidari A, Catanzaro A, Cadena J, Chin-Hong P, Spellberg B, Johnson R.  Adjunctive Corticosteroid Therapy in the Treatment of Coccidioidal Meningitis.  2017.  Clin Infect Dis.  65:338-41.

172. Cheng BL, Nielsen TB, Pantapalangkoor P, Zhao F, Lee JC, Montgomery CP, Luna B, Spellberg B, Daum RS.  Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection.  2017.  Human Vaccine Immunother.  13:1609-14.  PMCID: PMC5512765.

171. Spellberg B.  Sacubitril-Valsartan in Heart Failure.  2017.  Ann Int Med.  166:680.

170. Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA.  Can ceftazidime/avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae?  2017.  Antimicrob Agents Chemother.  61:e02243-16.

169. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B.  Clinical and Pathophysiological Overview of Acinetobacter Infections: A Century of Challenges.  2017.  Clin Microbiol Reviews.  30:409-447.  PMCID: PMC5217799

168. Spellberg B, Bartlett JB, Gilbert DN.  How to Pitch an Antibiotic Stewardship Program (ASP) to the Hospital C-Suite.  2016.  Open Forum Infect Dis.  3(4):ofw210.  PMCID: PMC5104972.

167. Spellberg B, Marr K, Brass EP.  Regulatory pathways for new antimicrobial agents: Trade-offs to keep the perfect from being the enemy of the good.  2016.  Clin Pharmacol Ther.  100:597-9.  PMCID: PMC5242400.

166. Spellberg B, Bonomo RA.  Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: “We’re Gonna Need a Bigger Boat.”  2016.  Clin Infect Dis.  63:1619-21. PMCID: PMC5146721.

165. Wei EK, Sarff L, Spellberg B.  Debunking the July Effect Myth.  2016.  J Patient Saf.  ePub.

164. Spellberg B.  The New Antibiotic Mantra: “Shorter Is Better.”  2016.  JAMA Int Med. 176:1254-5.  PMCID: PMC5233409.

163. Sartelli M…Spellberg B…Viale P (total of >100 authors).  Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).  2016.  World J Emerg Surg.  11:33-55.

162. Spellberg B, Brass EP.  The VITAL Study: Case Control Studies Are Hypothesis-Generating.  2016.  Lancet Infect Dis.  16:866.

161. Spellberg B.  Trimethoprim–Sulfamethoxazole for Uncomplicated Skin Abscess.  2016.  N Eng J Med. 375:284.

160. Wong DW, Spellberg.  Leveraging Antimicrobial Stewardship Teams to Address the Threat of Carbapenem-Resistant Enterobacteriaceae.  2016.  Virulence.  17:1-8.

159. Spellberg B, Srinivasan A, Chambers HF.  Empowering Antibiotic Stewardship Will Require New Societal Approaches.  2016.  JAMA.  315:1229-30.  PMCID: PMC5611826.

158. Rojas LJ, Taracila MA, Papp-Wallace KM, Bethel CR, Caselli E, Romagnoli C, Winkler ML, Spellberg B, Prati F, Bonomo RA.  Boronic Acid Transition State Inhibitors Active against KPC and Other Class A β-Lactamases: Structure-Activity Relationships as a Guide to Inhibitor Design.  2016.  60:1751-9.

157. Russo TA, Spellberg B, Johnson JR.  Important Complexities of the Antivirulence Target Paradigm:  a Novel Ostensibly Resistance-Avoiding Approach for Treating Infections.  2016.  J Infect Dis.  213:901-3.  PMCID: PMC4760422.

156. Spellberg B, Brass EP.  Non-inferiority does not mean non-inferior.  2016.  Clin Infect Dis.  62:525-6.

155. Bruhn KW, Dekitani K, Nielsen T, Pantapalangkoor P, Spellberg B.  Ly6G-mediated depletion of neutrophils is dependent on macrophages.  2015.  Res Immunol.  6:5-7.  PMCID: PMC4711394.

154. Nielsen TB, Bruhn KW, Pantapalangkoor P, Junus JL, Spellberg B.  Cryopreservation of virulent Acinetobacter baumannii to reduce variability of in vivo studies.  2015.  BMC Micro Method.  15:252.  PMCID: PMC4630970.

153. Bruhn KW, Spellberg B.  Transferrin-mediated iron sequestration as a novel therapy for bacterial and fungal infections.  2015.  Curr Opin Microbiol.  27:57-61.  PMCID: PMC4659759

152. Spellberg B, Doi Y.  The Rise of Fluoroquinolone-Resistant E. coli in the Community: Scarier than We Thought.  2015.  J Infect Dis.  212(12):1853-5.  PMCID: PMC4620434

151. Broglio KR, Daar ES, Quintana M, Yuan Y, Kalsekar A, Spellberg B, Lewis RJ, Akker DV, Detry MA, Le T, Berry SM.  A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.  2015.  J Comp Eff Res.  4:101-14.

150. Spellberg B, Bonomo R.  Combination Therapy for Extreme Drug Resistant (XDR) Acinetobacter baumannii: Ready for Prime-Time?  2015.  Crit Care Med.  43:1332-4.  PMCID: PMC4620434

149. Spellberg B, Bartlett JG, Wunderink R, Gilbert DN.  Novel Approaches Are Needed to Develop Tomorrow’s Antibacterial Therapies.  2015.  Am J Resp Crit Care Medicine.  191:135-40. PMCID: PMC4347440.

148. Fleischman RJ, Kaji AH, Diaz VM, McKenzie K, Soltero P, Van Natta TL, Spellberg B.  A Simple Intervention to Improve Hospital Flow from Emergency Department to Inpatient Units.  2015.  JAMA Internal Med.  175:289-90.

147. Bruhn KW, Pantapalangkoor P, Nielsen T, Tan B, Junus J, Hujer KM, Wright MS, Bonomo RA, Adams MD, Chen W, Spellberg B.  Host Fate Is Rapidly Determined by Innate Effector-Microbial Interactions During Acinetobacter baumannii Bacteremia.  2015.  J Infect Dis.  211(8):1296-305.  PMCID: PMC4447835.

146. Park H, Solis NV, Louie JS, Spellberg B, Rodriguez N, Filler SG.  Different Tumor Necrosis Factor α Antagonists Have Different Effects on Host Susceptibility to Disseminated and Oropharyngeal Candidiasis in Mice.  2014.  Virulence.  5:625-9.  PMCID: PMC4105312.

145. Chang DW, Huyhn R, Sandoval E, Han N, Coil CJ, Spellberg BJ.  Volume of Fluids Administered During Resuscitation for Severe Sepsis and Septic Shock and the Development of the Acute Respiratory Distress Syndrome.  2014.  J Crit Care.  29(6):1011-5

144. David MZ, Daum RS, Bayer AS, Chambers HF, Fowler VG, Miller LG, Ostrowsky B, Baesa A, Boyle-Vavra S, Eells SJ, Garcia-Houchins S, Gialanella P, Macias-Gil R, Rude TH, Ruffin F, Seith J, Volinski J, Spellberg B.  Staphylococcus aureus Bacteremia at Five U.S. Academic Medical Centers, 2008-2011: Significant Geographic Variation in Community-Onset Infections.  2014.  Clin Infect Dis.  59:798-807. PMCID: PMC4200044

143. Spellberg B, Gilbert DN.  The Future of Antibiotics and Resistance: A Tribute to a Career of Leadership by John Bartlett.  2014.  Clin Infect Dis.  59(S2):S71-5.  PMCID: PMC4176319

142. Spellberg B, Shlaes D.  Prioritized Current Unmet Needs for Antibacterial Therapies.  2014.  Clin Pharm Ther.  96:151-3.

141. Kim D, Spellberg B.  Does Real-Time Feedback to Residents or Attendings Improve Medical Documentation?  2014.  J Hospital Practice.  42:123-30.

140. Spellberg B.  Community acquired pneumonia.  2014.  New Eng J Med.  370:1861-2.

139. Chambers HF, Bartlett JG, Bonomo RA, Chiou C, Cosgrove SE, Cross HR, Daum RS, Downing M, Evans SR, Knisely J, Kreiswirth BN, Lautenbach E, Mickley BS, Patel R, Pettigrew MM, Rodvold KA, Spellberg B, Fowler VG Jr. Antibacterial Resistance Leadership Group: Open for Business.  2014.  Clin Infect Dis.  58:1571-6.

138. Shimizu E, Glaspy K, Witt MD, Poon K, Black S, Schwartz S, Bholat T, Diaz N, Kuo A, Spellberg B.  Readmissions at a public safety net hospital.  2014.  PLoS One.  9:e91244. PMCID: PMC3949745.

137. Spellberg B.  The future of antibiotics.  2014.  Critical Care.  18:228-35.  PMCID: PMC4075146.

136. Lin L, Pantapalangkoor P, Tan B, Bruhn K, Ho T, Nielsen T, Skaar EP, Zhang Y, Bai R, Wang A, Doherty TM, Spellberg B.  Transferrin iron starvation therapy for lethal bacterial and fungal infections.  2014.  J Infect Diseases.  210:254-64.  PMCID: PMC4092247.

135. Luo G, Spellberg B, Gebremariam T, Lee H, Xiong YQ, French SW, Bayer A, Ibrahim AS.  Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia.  2013.  Eur J Clin Microbiol Infect Dis.  33:845-51.  PMCID: PMC4090217.

134. Spellberg B.  Antibiotic Judo: Working Gently with Prescriber Psychology to Overcome Inappropriate Use.  2014.  JAMA Int Med.  174:432-3.  PMCID: PMC4064591.

133. Spellberg B, Bonomo R.  The Deadly Impact of Extreme Drug Resistance in Acinetobacter baumannii.  2014.  Critical Care Med.  42:1289-91. PMCID: PMC4184139.

132. Spellberg B, Rex J.  The Value of Single-Pathogen Antibacterial Agents.  2013.  Nature Reviews Drug Discovery.  12:963.  PMCID: PMC4012226.

131. Shlaes D, Sahm D, Opiela C, Spellberg B.  The FDA Reboot of Antibiotic Development.  2013.  Antimicrob Agents Chemother.  57:4605-7.  PMCID: PMC3811409.

130. Montgomery CP, Daniels MD, Zhao F, Spellberg B, Chong AS, Daum RS.  Local inflammation exacerbates the severity of Staphylococcus aureus skin infection.  2013.  PLoS One.  8:e69508.  PMCID: PMC3702601.

129. Thompson G, Wang S, Bercovitch R, Bolaris M, Van Den Akker D, Taylor S, Lopez R, Catanzaro A, Cadena J, Chin-Hong P, Spellberg B.  Routine CSF analysis in coccidioidomycosis is not required.  2013.  PLoS One.  8:e64249.

128. Spellberg B.  Endpoints in trials of treatment for skin infections.  2013.  JAMA.  309:2091-2.

127. Spellberg B, Bonomo RA.  “Airborne Assault:” A New Dimension in Acinetobacter baumannii Transmission.  2013.  Crit Care Medicine.  41:2042-4.  PMCID: PMC3815473.

126. Mendez CM, Harrington DW, Christenson P, Spellberg B.  Impact of Hospital Variables on Case Mix Index as a Marker of Disease Severity.  2013.  Population Health Management.  17:28-34.  PMCID: PMC3931432.

125. Bartlett JG, Gilbert D, Spellberg B.  Seven ways to preserve the miracle of antibiotics.  2013.  Clin Infect Dis.  56:1445-50.

124. Spellberg B, Taylor-Blake B.  On the Exoneration of Dr. William H. Stewart: Debunking an Urban Legend.  2013. Int J Medical Poverty.  2:3.  PMCID: PMC3707092

123. Spellberg B, Bartlett JG, Gilbert DN.  The Future of Antibiotics and Resistance.  2013.  New Eng J Med.  368:299-302.  PMCID: PMC3617123

122. Russo T, Beanan J, Olson R, MacDonald U, Cox A, St. Michael F, Vinogradov E, Spellberg B, Luke-Marshall N, Campagnari A.  The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization.  2013.  Infect Immun.  81:915-22. PMCID: PMC3584894

121. Spellberg B, Harrington D, Black S, Sue D, Stringer W, Witt M.  Capturing the diagnosis:  an internal medicine education program to improve documentation.  2013.  Am J Med.  126:739-43.

120. Lin L, Tan B, Pantapalangkoor P, Ho T, Hujer AM, Taracila MA, Bonomo RA, Spellberg B.  Acinetobacter baumannii rOmpA Vaccine Dose Alters Immune Polarization and Immunodominant Epitopes.  2013.  Vaccine.  31:313-8.  PMCID: PMC3557524.

119. Spellberg B, Sue D, Chang D, Witt M.  Change in Cross-Cover Calls at Night after a Work Hour Restriction Process Change.  2013.  JAMA Int Med.  173:707-9.

9-33.

bottom of page